Clinical Trial

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-20; most recent amendment 2026-05-13.
Status change: Not Yet Recruiting → Recruiting 2025-06-06
Trial Details
NCT Number NCT06994143
Lead Sponsor Cullinan Therapeutics Inc.
Conditions Rheumatoid Arthritis (RA
Enrollment 37 participants
Start Date 2025-05-19
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-15